Expand Your Treatment Focus with the TearCare® System
Expand Your Treatment Focus with the TearCare® System
Get a Closer Look at One of the Most Studied Devices in MGD
American Academy of Optometry, October 2022, San Diego, CA
Tom Chester, OD,
Tanner Ferguson, MD,
Emma Chester
Cornea, September 2021
TearCare for the Treatment of Meibomian Gland Dysfunction in Adult Patients With Dry Eye Disease: A Masked Randomized Controlled Trial
Preeya K. Gupta, MD
Edward J. Holland, MD,
John Hovanesian, MD,
Jennifer Loh, MD,
Mitchell A. Jackson, MD,
Paul M. Karpecki, OD,
Kavita Dhamdhere, MD, PhD
Clinical Ophthalmology, August 2022
Edward J Holland, MD,
Jennifer Loh, MD,
Marc Bloomenstein, OD,
Vance Thompson, MD,
David Wirta, MD,
Kavita Dhamdhere, MD, PHD
Clinical Ophthalmology, December 2020
A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCare® System as a Safe and Effective Blink-Assisted Eyelid Device for the Treatment of Dry Eye Disease
Paul Karpecki, OD,
David Wirta, MD,
Smajo Osmanovic, MD,
Kavita Dhamdhere, MD, PhD
Optometry and Vision Science, June 2021
Thomas Chester, OD
Clinical Ophthalmology, January 2019
David Badawi, MD
Clinical Ophthalmology, April 2018
A Novel System, TearCare®, for the Treatment of the Signs and Symptoms of Dry Eye Disease
Learn more about the TearCare® System
Indications for Use: The TearCare® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.
The TearCare® System may not be right for everyone. Please see Instructions for Use or visit TearCare.com for Contraindications, Warnings, Precautions and Adverse Events.
- 4040 Campbell Ave, Suite 100
- Menlo Park CA 94025
- T: 877-266-1144
- E: tearcare@sightsciences.com
© 2023 Sight Sciences, Inc. 11/22 TC-2130-US.v3 TearCare® is a registered trademark of Sight Sciences.